Revolution Medicines, a clinical-stage precision oncology firm based in Redwood City, California, focuses on developing targeted therapies, including RAS(ON) inhibitors and companion inhibitors, currently in clinical development. The company went public on February 13, 2020, and employs 411 staff.
Mark A Goldsmith sold 30,000 shares of RVMD on 7 November at $60.31 per share, worth a total of $1.8M. They now own 347,863 RVMD shares, or a 8% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.